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Abstract The safety of other biologic therapies in rheu-
matoid arthritis (RA) following B cell-depletion therapy
with rituximab has not been established. This retrospective
chart review of patients attending an outpatient rheuma-
tology clinic aimed to assess the incidence of adverse
events in patients receiving biologic agents to treat RA
after an inadequate response or intolerance to rituximab.
The charts of 22 patients (18 female; mean age 59 years)
were reviewed. Duration of RA was [2 years. Before rit-
uximab, patients had failed one (n = 10), two (n = 4) or
three (n = 7) biologic therapies: 1 patient started on rit-
uximab as a first-line biologic. Eighteen patients stopped
rituximab due to an inadequate clinical response, while
four patients stopped due to adverse events. The mean time
to starting a new biologic after rituximab was 4 months,
although five patients were started within 1 month of the
last rituximab infusion. Abatacept (41%) was the most
common biologic used after rituximab. The mean follow-
up time from the last rituximab infusion was 14 months.
Adverse events occurring after rituximab therapy, but
before initiation of a new biologic, included disseminated
herpes zoster and aseptic meningitis (both required hospi-
talization). Adverse events recorded after starting a new
biologic post-rituximab included rash, carbuncle, upper
respiratory tract infection, urinary tract infection, pneu-
monia, and eczema, but none was classified as serious.
Most of these events occurred in patients receiving abata-
cept. In conclusion, in this retrospective analysis, no seri-
ous adverse events were recorded in patients who received
biologic agents following rituximab therapy.
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Introduction
Rheumatoid arthritis (RA), a systemic autoimmune disease
characterized by chronic inflammation of the joints, affects
approximately 1% of the Caucasian population and is
associated with functional disability and a decreased life
span [1]. The development of targeted biologic therapies,
such as antitumor necrosis factor-a (anti-TNF-a) agents,
represented a substantial advance in the treatment of RA.
Even so, 25–40% of patients fail to respond to or become
refractory to treatment with TNF inhibitors [2–4].
Treatment options for patients with an inadequate
response to TNF inhibitors include rituximab, a genetically
engineered monoclonal antibody that targets CD20-posi-
tive B cells [5, 6]. Rituximab is given as a course of two
infusions of 1,000 mg, 2 weeks apart, and is licensed for
use in combination with methotrexate in adults with
moderate-to-severe active RA who have responded inade-
quately to one or more TNF inhibitors. In patients who
develop an inadequate response to rituximab after one or
more courses, further treatment options are limited, and
many physicians return to biologic agents; in most cases,
TNF inhibitors or abatacept. Given the long-lasting effects
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of rituximab on B cell levels and the potential for pro-
tracted effects on the host immune defense system [7],
there are some concerns that the use of a new biologic
agent against a background of prior rituximab therapy may
present an additional safety risk to the patient [8]. To
investigate the safety of biologic therapy in patients who
previously received and developed an inadequate response
to rituximab therapy, we conducted a retrospective chart
review of patients at a single US center.
Methods
The study was a retrospective chart review of patients with
RA who received at least one infusion of rituximab and were
then switched to another biologic agent (etanercept, ada-
limumab, infliximab, or abatacept) during a 2-year period
(June 2006 to July 2008). All patients attended an outpatient
rheumatology clinic affiliated to a community hospital near
Philadelphia, PA, USA. Data collected included demo-
graphic information, duration of RA, and antirheumatic
drugs used. Detailed information was collected on any
adverse event reported during the study period.
Results
Charts were reviewed from 22 patients, of whom 18 (82%)
were female. The mean (±SD) age of the patients was
59 ± 13 years, and all patients had RA of [2 years’
duration. All but one patient had failed at least one biologic
therapy before starting rituximab therapy (10, 4, and 7
patients had failed 1, 2, and 3 biologics, respectively).
Most patients (n = 16) had received a single course of
rituximab (2 9 1,000 mg infusions given 2 weeks apart).
Three patients had received two courses, and one patient was
unable to complete a third course due to the development of
aseptic meningitis following the first infusion of that course.
The remaining two patients stopped rituximab after the first
infusion of the first course due to adverse events (one case
each of acute hypertensive reaction and cellulitis).
The reason for stopping rituximab therapy was inade-
quate clinical response in 18 patients and adverse events
in the remaining four patients. Adverse events recorded
during rituximab treatment, but before initiation of a new
biologic, are listed in Table 1. Two events required hos-
pitalization: one case of aseptic meningitis that occurred
1 week following the first rituximab infusion of Course 3
and one case of disseminated herpes zoster that occurred
1 month after the second rituximab infusion of Course 2.
The patient with aseptic meningitis required hospitaliza-
tion but improved with symptomatic treatment and was
subsequently discharged; this patient also had a history of
systemic lupus erythematosus. The patient with dissemi-
nated herpes zoster was also admitted to hospital but
responded to antiviral therapy before being discharged
home.
New biologic therapy was initiated a mean of 4 months
(range 1–12 months) after the cessation of rituximab; five
patients (23%) began treatment within 1 month of their last
rituximab infusion. Abatacept was the most common bio-
logic agent used after rituximab (n = 9; 41%); the other
biologic therapies used were etanercept (n = 6), ada-
limumab (n = 5), and infliximab (n = 2). The mean fol-
low-up time after the last rituximab infusion was
14 months (range 7–24 months). Adverse events recorded
in patients receiving biologics after rituximab are shown in
Table 2. A total of seven adverse events occurred in six
patients, three of whom were receiving abatacept. None of
the seven adverse events recorded during this period was
considered serious and none required inpatient hospital-
ization. Occurrence of an adverse event did not appear to
be related to the number of prior rituximab courses or to the
duration of the new biologic therapy. The period between
the last rituximab infusion and the first dose of the new
biologic varied from 1 to 12 months among patients who
experienced an adverse event. Among the five patients who
began treatment with a biologic within 1 month of their last
Table 1 Adverse events during rituximab treatment before initiation of new biologic therapy
Adverse event No. of rituximab
courses received
Time of onset of adverse event
after last rituximab infusion
No. of biologic therapies
before rituximab
Aseptic meningitisa 2.5b 1 week 1
Disseminated herpes zostera 2 1 month 1
Cellulitis 0.5c 1 week 3
Sinusitis 1 4 months 1
a Patient required hospitalization
b Patient did not receive second infusion of third course
c Patient did not receive second infusion of first course
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rituximab infusion, only one patient developed an infection
(a mild urinary tract infection).
Discussion
The results of this retrospective chart review indicate that
patients who have an inadequate response to rituximab or
who are unable to tolerate rituximab can be restarted safely
on a new biologic therapy (TNF inhibitor or abatacept). To
date, no serious adverse events requiring hospitalization
have been recorded among 22 patients who were treated
with etanercept, adalimumab, infliximab, or abatacept fol-
lowing one, two or three courses of rituximab therapy. There
was no clear pattern to the type of nonserious adverse events
(five infections and two dermatologic events) recorded
during biologic therapy post-rituximab. These types of
adverse events are typically observed in patients receiving
TNF inhibitors [9, 10] or abatacept [11]. Occurrence of an
adverse event appeared unrelated to the number of prior
rituximab courses received or to the interval between stop-
ping rituximab and starting the new therapy. Indeed, there
was only one mild infection among the five patients who
started a new biologic 1 month after stopping rituximab.
Similarly, the type and duration of new therapy did not
appear to predict the occurrence of an adverse event.
Overall, although the patient numbers are small, there is
no evidence from this review of any increase in the inci-
dence of nonserious or serious adverse events in patients
who are treated with a biologic agent following a period of
rituximab therapy compared with the incidence during
rituximab treatment. This finding is consistent with long-
term follow-up data from the rituximab clinical trial pro-
gram: a recent analysis, involving 185 patients who
received rituximab plus methotrexate and who subse-
quently received another biologic agent, with follow-up for
at least 48 months, showed that 13 serious infections
occurred during rituximab therapy (6.99 events/100 patient
years), compared with 10 serious infections after initiation
of a new biologic (5.49 events/100 patient years) [12]. The
infections were reported to be variable and typical for
patients with RA; no opportunistic or fatal infection
occurred.
Our study is limited by a number of factors, including:
the small size of the patient cohort; the use of a single
sampling center; the retrospective nature of the analysis;
and the relatively short follow-up period. Nonetheless,
the results provide supportive evidence from real-life
practice that biologic agents can be safely given to
patients who have discontinued therapy with rituximab.
Further results from the clinical trial program extension
studies and from national registries and other postmar-
keting surveillance will be required before firm conclu-
sions can be drawn regarding the safety of biologic
therapies after rituximab.
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Rash (erythema nodosum) Etanercept 5 2.5a 4 1
Carbuncle Abatacept 9 1 3 2
Urinary tract infection Adalimumab 1 0.5b 1 1
Upper respiratory tract infection Abatacept 1 1 4 1
Abataceptc 1 0.5b 12 3
Pneumonia Abataceptc 5 0.5b 12 3
Eczema Infliximab 6 1 3 1
a Patient did not receive second infusion of third course
b Patient did not receive second infusion of first course
c Two adverse events (upper respiratory tract infection and pneumonia) occurred in the same patient
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